Product Information
ERYTHROMYCIN 250 MG TABLET is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $1.9552 per EA under NDC 75834024201. Its NADAC has been published 247 times since Jan 12, 2022.
FDA first approved this application on Jun 28, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Nivagen Pharmaceuticals Inc.NDC
75834024201
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERYTHROMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA213628FDA Approved
6/28/2021
TE Code
AB
On Market Since
7/15/2021
Pharmacological Classes
Price Statistics
The NADAC for ERYTHROMYCIN 250 MG TABLET has been published 247 times since Jan 12, 2022, and over the history we have for it it has declined 74.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9552 per EA |
|---|---|
| All-time high | $8.8424 (Aug 10, 2022) |
| All-time low | $1.3349 (May 22, 2024) |
| 52-week high | $1.9552 |
| 52-week low | $1.3571 |
| Median price | $2.0483 |
| Average price | $3.6179 |
| Largest weekly change | -54.7% (Apr 17, 2024) |
| Weeks tracked | 247 |
| Tracking since | Jan 12, 2022 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Nivagen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ERYTHROMYCIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYTHROMYCIN 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN 250 MG TABLET, manufactured by Nivagen Pharmaceuticals Inc., is $1.9552 per EA (NDC 75834024201), effective Sep 30, 2026.
How has the price of ERYTHROMYCIN 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for ERYTHROMYCIN 250 MG TABLET has declined 74.8%. It has been tracked across 247 weekly CMS publications since Jan 12, 2022.
What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN 250 MG TABLET?
Since Jan 12, 2022, the NADAC for ERYTHROMYCIN 250 MG TABLET has ranged from a low of $1.3349 (May 22, 2024) to a high of $8.8424 (Aug 10, 2022), with a median of $2.0483 per EA.
Are there cheaper alternatives to ERYTHROMYCIN 250 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ERYTHROMYCIN DR 250 MG TABLET, is $1.9250 per EA — about 2% below ERYTHROMYCIN 250 MG TABLET.
Who manufactures ERYTHROMYCIN 250 MG TABLET?
ERYTHROMYCIN 250 MG TABLET (NDC 75834024201) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.